羟基喜树碱致死性不良反应的发生机制分析
|
摘要
<正>羟基喜树碱(10-hydroxycamptothecin,HCPT)是植物来源的拓扑异构酶I抑制剂,是喜树(Camptotheca acuminata)有效成分喜树碱的衍生物。在我国,HCTP被批准用于治疗转移性结直肠癌~([1-3])。在结构上,HCTP与伊利替康的药理活性代谢物7-乙基-10-羟基喜树碱(SN-38)的差别只有一个乙基
引文
[1]DARZYNKIEWICZ Z,BRUNO S,DEL BINO G,et al.The cell cycle effects of camptothecin[J].Ann N Y Acad Sci,1996,803(10):93-100.
[2]ZHANG R,LI Y,CAI Q,et al.Chambless B.Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin,an inhibitor of topoisomerase I[J].Cancer Chemother Pharmacol,1998,41(3):257-267.
[3]WANG SL,LIN SY,HSIEH TF,et al.Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state[J].J Pharm Biomed Anal,2007,43(4):457-463.
[4]INNOCENTI F,UNDEVIA SD,IYER L,et al.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan[J].J Clin Oncol,2004,22(19):1382-1388.
[5]IYER L,KING CD,WHITINGTON PF,et al.Genetic predisposition to the metabolism of irinotecan(CPT-11):role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite(SN-38)in human liver microsomes[J].J Clin Invest,1998,101(56):847-854.
[6]TOFFOLI G,CECCHIN E,CORONA G,et al.The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer[J].J Clin Oncol,2006,24(1):3061-3068.
[7]JADA SR,LIM R,WONG CI,et al.Role of UGT1A1*6,UGT1A1*28 and ABCG2c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients[J].Cancer Sci,2007,98(3):1461-1467.
[8]MINAMI H,SAI K,SAEKI M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and*28[J].Pharmacogenet Genomics,2007,17(15):497-504.
[9]HAN JY,LIM HS,SHIN ES,et al.Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin[J].J Clin Oncol,2006,24(1):2237-2244.
[2]ZHANG R,LI Y,CAI Q,et al.Chambless B.Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin,an inhibitor of topoisomerase I[J].Cancer Chemother Pharmacol,1998,41(3):257-267.
[3]WANG SL,LIN SY,HSIEH TF,et al.Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state[J].J Pharm Biomed Anal,2007,43(4):457-463.
[4]INNOCENTI F,UNDEVIA SD,IYER L,et al.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan[J].J Clin Oncol,2004,22(19):1382-1388.
[5]IYER L,KING CD,WHITINGTON PF,et al.Genetic predisposition to the metabolism of irinotecan(CPT-11):role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite(SN-38)in human liver microsomes[J].J Clin Invest,1998,101(56):847-854.
[6]TOFFOLI G,CECCHIN E,CORONA G,et al.The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer[J].J Clin Oncol,2006,24(1):3061-3068.
[7]JADA SR,LIM R,WONG CI,et al.Role of UGT1A1*6,UGT1A1*28 and ABCG2c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients[J].Cancer Sci,2007,98(3):1461-1467.
[8]MINAMI H,SAI K,SAEKI M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and*28[J].Pharmacogenet Genomics,2007,17(15):497-504.
[9]HAN JY,LIM HS,SHIN ES,et al.Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin[J].J Clin Oncol,2006,24(1):2237-2244.